|
| 37683132 | Optimization of Advanced Molecular Genetic Testing Utilization in Hematopathology: A Goldilocks Approach to Bone Marrow Testing. | JCO Oncol Pract | 2024 |
| 37163357 | FLT3-ITD does not predict inferior prognosis in acute myeloid leukemia patients aged â¿¥60 years. | Blood Adv | 2023 |
| 37595362 | PPM1D modulates hematopoietic cell fitness and response to DNA damage and is a therapeutic target in myeloid malignancy. | Blood | 2023 |
| 37898151 | Germline predisposition traits in allogeneic hematopoietic stem-cell transplantation for myelodysplastic syndromes: a survey-based study and position paper on behalf of the Chronic Malignancies Working Party of the EBMT. | | 2023 |
| 36947201 | Utility of targeted gene sequencing to differentiate myeloid malignancies from other cytopenic conditions. | Blood Adv | 2023 |
| 37451200 | Incidence and predictors of anthracycline-related left ventricular dysfunction in acute myeloid leukemia. | Leuk Res | 2023 |
| 37483562 | Prediction of risk for myeloid malignancy in clonal hematopoiesis. | NEJM Evid | 2023 |
| 37419244 | Outlier Expression of Isoforms by Targeted or Total RNA Sequencing Identifies Clinically Significant Genomic Variants in Hematolymphoid Tumors. | J Mol Diagn | 2023 |
| 35286378 | Impact of diagnostic genetics on remission MRD and transplantation outcomes in older patients with AML. | Blood | 2022 |
| 35969835 | Germ line predisposition variants occur in myelodysplastic syndrome patients of all ages. | Blood | 2022 |
| 35904492 | Impaired Proteolysis of Noncanonical RAS Proteins Drives Clonal Hematopoietic Transformation. | Cancer Discov | 2022 |
| 35584376 | Allelic complexity of KMT2A partial tandem duplications in acute myeloid leukemia and myelodysplastic syndromes. | Blood advances | 2022 |
| 35704596 | Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine. | Sci Transl Med | 2022 |
| 36485102 | Transplant for TP53-mutated MDS and AML: because we can or because we should? | | 2022 |
| 34793200 | Donor Clonal Hematopoiesis and Recipient Outcomes After Transplantation. | J Clin Oncol | 2022 |
| 35289704 | Outcomes of antifungal prophylaxis for newly diagnosed AML patients treated with a hypomethylating agent and venetoclax. | Leuk Lymphoma | 2022 |
| 34507355 | Genomic profiling of a randomized trial of interferon-α vs hydroxyurea in MPN reveals mutation-specific responses. | Blood advances | 2022 |
| 35015684 | BCOR and BCORL1 Mutations Drive Epigenetic Reprogramming and Oncogenic Signaling by Unlinking PRC1.1 from Target Genes. | Blood Cancer Discov | 2022 |
| 35081257 | Prediction of life-threatening and disabling bleeding in patients with AML receiving intensive induction chemotherapy. | Blood Adv | 2022 |
| 35349491 | Expansion, persistence, and efficacy of donor memory-like NK cells infused for posttransplant relapse. | J Clin Invest | 2022 |
| 34614506 | Adding venetoclax to fludarabine/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and active. | Blood Adv | 2021 |
| 34019641 | The clinical and functional effects of TERT variants in myelodysplastic syndrome. | Blood | 2021 |
| 33637765 | Distinct genetic pathways define pre-malignant versus compensatory clonal hematopoiesis in Shwachman-Diamond syndrome. | Nat Commun | 2021 |
| 33837971 | Pretreatment clinical and genetic factors predict early post-treatment mortality in fit AML patients following induction. | Am J Hematol | 2021 |
| 33570623 | Somatic GATA2 mutations define a subgroup of myeloid malignancy patients at high risk for invasive fungal disease. | Blood advances | 2021 |
| 33512458 | Modeling and targeting of erythroleukemia by hematopoietic genome editing. | Blood | 2021 |
| 34521115 | Clonal hematopoiesis in sickle cell disease. | Blood | 2021 |
| 32603763 | Targeted Informatics for Optimal Detection, Characterization, and Quantification of FLT3 Internal Tandem Duplications Across Multiple Next-Generation Sequencing Platforms. | J Mol Diagn | 2020 |
| 31895053 | X-linked macrocytic dyserythropoietic anemia in females with an ALAS2 mutation. | J Clin Invest | 2020 |
| 31837959 | Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial. | Lancet Haematol | 2020 |
| 32097457 | Stem cell donors should not be screened for clonal hematopoiesis. | Blood advances | 2020 |
| 33367544 | Short telomere length predicts nonrelapse mortality after stem cell transplantation for myelodysplastic syndrome. | Blood | 2020 |
| 32736377 | Clonal hematopoiesis in the inherited bone marrow failure syndromes. | Blood | 2020 |
| 32781289 | A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes. | Biol Blood Marrow Transplant | 2020 |
| 30992267 | Engineered Bcor mutations lead to acute leukemia of progenitor B-1 lymphocyte origin in a sensitized background. | Blood | 2019 |
| 30926971 | Genomic subtyping and therapeutic targeting of acute erythroleukemia. | Nat Genet | 2019 |
| 30047417 | Significance of Clonal Mutations in Bone Marrow Failure and Inherited Myelodysplastic Syndrome/Acute Myeloid Leukemia Predisposition Syndromes. | Hematology/Oncology Clinics of North America | 2018 |
| 30381416 | Older adults with acute myeloid leukemia treated with intensive chemotherapy: "old" prognostic algorithms may not apply. | Haematologica | 2018 |
| 28177873 | Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation. | New England Journal of Medicine | 2017 |
| 28642360 | Now I cuss less about ICUS. | Blood | 2017 |
| 28600338 | The relative utilities of genome-wide, gene panel, and individual gene sequencing in clinical practice. | Blood | 2017 |
| 28446434 | Donor-engrafted CHIP is common among stem cell transplant recipients with unexplained cytopenias. | Blood | 2017 |
| 29222292 | Uncoding the genetic heterogeneity of myelodysplastic syndrome. | Hematology. American Society of Hematology. Education Program | 2017 |
| 29296824 | Systematic <i>STAT3</i> sequencing in patients with unexplained cytopenias identifies unsuspected large granular lymphocytic leukemia. | Blood Adv | 2017 |
| 29156197 | Mutational complexity in myelodysplasia. | Best Practice and Research in Clinical Haematology | 2017 |
| 29064024 | Measurement of Residual Disease in Acute Myeloid Leukemia. | Current Hematologic Malignancy Reports | 2017 |
| 28068180 | Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma. | J Clin Oncol | 2017 |
| 27599292 | Functionally identifiable apoptosis-insensitive subpopulations determine chemoresistance in acute myeloid leukemia. | J Clin Invest | 2016 |
| 27339098 | Validation and Implementation of a Custom Next-Generation Sequencing Clinical Assay for Hematologic Malignancies. | Journal of Molecular Diagnostics | 2016 |
| 26878232 | Rps14 haploinsufficiency causes a block in erythroid differentiation mediated by S100A8 and S100A9. | Nat Med | 2016 |